Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases

Journal of Biochemistry

Volumn 153, Issue 1, 2013, Pages 13-19

  Shibuya, Masabumi ^a  

^a JOBU UNIVERSITY   (Japan)

Author keywords

hypoxia; preeclampsia; tumor angiogenesis; VEGF; VEGFR

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; NEUTRALIZING ANTIBODY; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLEEDING; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; DRUG EFFICACY; DRUG SENSITIVITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVERALL SURVIVAL; PREECLAMPSIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEINURIA; RECEPTOR UPREGULATION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; THROMBOSIS; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; FEMALE; HUMANS; LYMPHANGIOGENESIS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PRE-ECLAMPSIA; PREGNANCY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84871633270     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvs136     Document Type: Review

References (54)

1. Ferrara, N. and Kerbel, R.S. (2005) Angiogenesis as a therapeutic target. Nature 438, 967-974
2. Shibuya, M. (2011) Involvement of Flt-1 (VEGFR-1) in cancer and preeclampsia. Proc. Jpn Acad. Ser. B Phys. Biol. Sci. 87, 167-178
3. Shibuya, M. and Claesson-Welsh, L. (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312, 549-560
4. Alitalo, K. and Carmeliet, P. (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227
5. Jakobsson, L., Bentley, K., and Gerhardt, H. (2009) VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem. Soc. Trans. 37, 1233-1236
6. Duchek, P., Somogyi, K., Jekely, G., Beccari, S., and Rorth, P. (2001) Guidance of cell migration by the Drosophila PDGF/VEGF receptor. Cell 107, 17-26
7. Yaniv, K., Isogai, S., Castranova, D., Dye, L., Hitomi, J., and Weinstein, B.M. (2006) Live imaging of lymphatic development in the zebrafish. Nat. Med. 12, 711-716
8. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S., Powell-Braxton, L., Hillan, K.J., and Moore, M.W. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442
9. Carmellet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kleckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawlling, J., Moons, L., Collen, D., Resau, W., and Nagy, A. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439
10. Pritchard-Jones, R.O., Dunn, D.B., Qiu, Y., Varey, A.H., Orlando, A., Rigby, H., Harper, S.J., and Bates, D.O. (2007) Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br. J. Cancer 97, 223-230
11. Karkkainen, M.J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T.V., Jeltsch, M., Jackson, D.G., Talikka, M., Rauvala, H., Betsholtz, C., and Alitalo, K. (2004) Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5, 74-80
12. Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, J.A., Hooper, A., Priller, J., De, Klerck, B., Compernolle, V., Daci, E., Bohlen, P., Dewerchin, M., Herbert, J.M., Fava, R., Matthys, P., Carmeliet, G., Collen, D., Dvorak, H.F., Hicklin, D.J., and Carmeliet, P. (2002) Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8, 831-840
13. Aase, K., von, Euler, G., Li, X., Ponten, A., Thoren, P., Cao, R., Cao, Y., Olofsson, B., Gebre-Medhin, S., Pekny, M., Alitalo, K., Betsholtz, C., and Eriksson, U. (2001) Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 104, 358-364
14. Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., and Sato, M. (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5, 519-524
15. De, Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N., and Williams, L.T. (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991
16. Heldin, C.H. and Westermark, B. (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283-1316
17. Takahashi, T., Yamaguchi, S., Chida, K., and Shibuya, M. (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-g and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768-2778
18. Takahashi, T., Ueno, H., and Shibuya, M. (1999) VEGF activates Protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221-2230
19. Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.-F., Breitman, M.L., and Schuh, A.C. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66
20. Sakurai, Y., Ohgimoto, K., Kataoka, Y., Yoshida, N., and Shibuya, M. (2005) Essential role of Flk-1 (vascular endothelial growth factor receptor-2) tyrosine residue-1173 in vasculogenesis in mice. Proc. Natl Acad. Sci. USA 102, 1076-1081
21. Sase, H., Watabe, T., Kawasaki, K., Miyazono, K., and Miyazawa, K. (2009) VEGFR2-PLCgamma1 axis is essential for endothelial specification of VEGFR2\+ vascular progenitor cells. J. Cell Sci. 122, 3303-3311
22. Xiong, Y., Huo, Y., Chen, C., Zeng, H., Lu, X., Wei, C., Ruan, C., Zhang, X., Hu, Z., Shibuya, M., and Luo, J. (2009) Vascular endothelial growth factor (VEGF) receptor-2 tyrosine 1175 signaling controls VEGFinduced von Willebrand factor release from endothelial cells via phospholipase C-gamma 1-and protein kinase A-dependent pathways. J. Biol. Chem. 284, 23217-23224
23. Sawano, A., Takahashi, T., Yamaguchi, S., Aonuma, T., and Shibuya, M. (1996) Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for Placenta Growth Factor (PlGF), which is related to Vascular Endothelial Growth Factor (VEGF). Cell Growth Diff 7, 213-221
24. Kendall, R.L. and Thomas, K.A. (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. USA 90, 10705-10709
25. Fong, G.H., Rossant, J., Gertsentein, M., and Breitman, M.L. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70
26. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., and Shibuya, M. (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl Acad. Sci. USA 95, 9349-9354
27. Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J.M., Senior, R.M., and Shibuya, M. (2002) MMP9 induction by Vascular Endothelial Growth Factor Receptor-1 is involved in lung specific metastasis. Cancer Cell 2, 289-300
28. Kaplan, R.N., Riba, R.D., Zacharoulis, S., Bramley, A.H., Vincent, L., Costa, C., MacDonald, D.D., Jin, D.K., Shido, K., Kerns, S.A., Zhu, Z., Hicklin, D., Wu, Y., Port, J.L., Altorki, N., Port, E.R., Ruggero, D., Shmelkov, S.V., Jensen, K.K., Rafii, S., and Lyden, D. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827
29. Murakami, M., Iwai, S., Hiratsuka, S., Yamauchi, M., Nakamura, K., Iwakura, Y., and Shibuya, M. (2006) Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocyte/macrophages. Blood 108, 1849-1856
30. Muramatsu, M., Yamamoto, S., Osawa, T., and Shibuya, M. (2010) VEGF-1 signaling promotes mobilization of macrophage-lineage cells from bone marrow and stimulateolid tumor growth. Cancer Res. 70, 8211-8221
31. Kerber, M., Reiss, Y., Wickersheim, A., Jugold, M., Kiessling, F., Heil, M., Tchaikovski, V., Waltenberger, J., Shibuya, M., Plate, K.H., and Machein, M.R. (2008) Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 68, 7342-7351
32. Niida, S., Kondo, T., Hiratsuka, S., Hayashi, S.-I., Amizuka, N., Noda, T., Ikeda, K., and Shibuya, M. (2005) Vascular endothelial growth factor receptor-1 signaling is essential for osteoclast development and bone-marrow formation in CSF-1-deficient mice. Proc. Natl Acad. Sci. USA 102, 14016-14021
33. Storkebaum, E., Lambrechts, D., Dewerchin, M., Moreno-Murciano, M.P., Appelmans, S., Oh, H., Van, Damme, P., Rutten, B., Man, W.Y., De., Mol, M., Wyns, S., Manka, D., Vermeulen, K., Van Den Bosch, L., Mertens, N., Schmitz, C., Robberecht, W., Conway, E.M., Collen, D., Moons, L., and Carmeliet, P. (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 8, 85-92
34. Dhondt, J., Peeraer, E., Verheyen, A., Nuydens, R., Buysschaert, I., Poesen, K., Van Geyte, K., Beerens, M., Shibuya, M., Haigh, J.J., Meert, T., Carmeliet, P., and Lambrechts, D. (2011) Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons. FASEB J. 25, 1461-1473
35. Kondo, K., Hiratsuka, S., Subbalakshmi, E., Matsushime, H., and Shibuya, M. (1998) Genomic organization of the flt-1 gene encoding for Vascular Endothelial Growth Factor (VEGF) Receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors. Gene 208, 297-305
36. Yamaguchi, S., Iwata, K., and Shibuya, M. (2002) Soluble Flt-1 (soluble VEGFR-1), a potent natural anti-angiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem. Biophys. Res. Commun. 291, 554-559
37. Ambati, B.K., Nozaki, M., Singh, N., Takeda, A., Jani, P.D., Suthar, T., Albuquerque, R.J., Richter, E., Sakurai, E., Newcomb, M.T., Kleinman, M.E., Caldwell, R.B., Lin, Q., Ogura, Y., Orecchia, A., Samuelson, D.A., Agnew, D.W. St, Leger, J., Green, W.R., Mahasreshti, P.J., Curiel, D.T., Kwan, D., Marsh, H., Ikeda, S., Leiper, L.J., Collinson, J.M., Bogdanovich, S., Khurana, T.S., Shibuya, M., Baldwin, M.E., Ferrara, N., Gerber, H.P., De, Falco, S., Witta, J., Baffi, J.Z., Raisler, B.J., and Ambati, J. (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443, 993-997
38. Maynard, S.E., Min, J.Y., Merchan, J., Lim, K.H., Li, J., Mondal, S., Libermann, T.A., Morgan, J.P., Sellke, F.W., Stillman, I.E., Epstein, F.H., Sukhatme, V.P., and Karumanchi, S.A. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658
39. Koga, K., Osuga, Y., Yoshino, O., Hirota, Y., Ruimeng, X., Hirata, T., Takeda, S., Yano, T., Tsutsumi, O., and Taketani, Y. (2003) Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metab. 88, 2348-2351
40. Levine, R.J., Maynard, S.E., Qian, C., Lim, K.H., England, L.J., Yu, K.F., Schisterman, E.F., Thadhani, R., Sachs, B.P., Epstein, F.H., Sibai, B.M., Sukhatme, V.P., and Karumanchi, S.A. (2004) Circulating angiogenic factors and the risk of preeclampsia. N. Engl J. Med. 350, 672-683
41. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., and Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl J. Med. 350, 2335-2342
42. Zhang, S., Ji, Y., Liu, X., Lu, X., Su, W., Zhang, D., Hao, F., Yi, F., Guo, L., Li, X., and Zheng, Y. (2010) Podocyte-specific VEGF down-regulation and pathophysiological development. IUBMB Life 62, 677-683
43. Veron, D., Villegas, G., Aggarwal, P.K., Bertuccio, C., Jimenez, J., Velazquez, H., Reidy, K., Abrahamson, D.R., Moeckel, G., Kashgarian, M., and Tufro, A. (2012) Acute Podocyte Vascular Endothelial Growth Factor (VEGF-A) knockdown disrupts alpha(V)beta(3) integrin signaling in the glomerulus. PLoS One 7, e40589
44. Dvorak, H.F. (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380
45. Gilbert, J.S., Babcock, S.A., and Granger, J.P. (2007) Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50, 1142-1147
46. Foidart, J.M., Schaaps, J.P., Chantraine, F., Munaut, C., and Lorquet, S. (2009) Dysregulation of anti-angiogenic agents (sFlt-1, PLGF and sEndoglin) in preeclampsia-a step forward but not the definitive answer. J. Reprod. Immunol. 82, 106-111
47. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364
48. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., and Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844
49. Peak, S.J. and Levin, V.A. (2010) Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag. Res. 2, 97-104
50. Casanovas, O., Hicklin, D.J., Bergers, G., and Hanahan, D. (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309
51. You, W.K., Sennino, B., Williamson, C.W., Falcó n, B., Hashizume, H., Yao, L.C., Aftab, D.T., and McDonald, D.M. (2011) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71, 4758-4768
52. Zuniga, R.M., Torcuator, R., Jain, R., Anderson, J., Doyle, T., Ellika, S., Schultz, L., and Mikkelsen, T. (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol. 91, 329-336
53. Osawa, T., Muramatsu, M., Wang, F., Tsuchida, R., Kodama, T., Minami, T., and Shibuya, M. (2011) Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via downregulating angiogenesis. Proc. Natl Acad. Sci. USA 108, 20725-20729
54. Awale, S., Lu, J., Kalauni, S.K., Kurashima, Y., Tezuka, Y., Kadota, S., and Esumi, H. (2006) Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res. 66, 1751-1757